SCHEMBL9976791

SCHEMBL9976791

Nc1ccc(CSSSSCc2ccc(N)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
CYP3A4 P08684 4/20 0.50
TSHR P16473 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
GFER P55789 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAOB P27338 4/20 0.42
MAOA P21397 2/20 0.42
NOS1 P29475 1/20 0.42
MAPT P10636 1/20 0.42
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3241999 0.89 ALDH1A1 (0.55) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL9976775 0.89 ACHE (0.54) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL20072374 0.80 ALDH1A1 (0.46) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL3244307 0.78 ALDH1A1 (0.55) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL9976788 0.74 IDO1 (0.50) ALDH1A1TDP1MEN1KMT2ANPC1
SCHEMBL9976773 0.74 IDO1 (0.50) ALDH1A1CYP3A4TDP1RAB9ACYP1A2
SCHEMBL23177886 0.74 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL14081380 0.74 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL514209 0.74 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRTDP1GFER
SCHEMBL514208 0.74 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRTDP1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
WO-2010045582-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY HIF1AN, HIF1A, HYOU1 ALDH1A1 301/4885CYP3A4 3440/4885TSHR 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.